12 March 2026 ORYZON expands patent protection for iadademstat with grant decision in Mexico covering combinations with PD-1/PD-L1 inhibitors
27 February 2026 ORYZON reports financial results and corporate update for quarter ended December 31st, 2025
24 February 2026 ORYZON receives European Medicines Agency approval to initiate a Phase II study of iadademstat in essential thrombocythemia